Verotina

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Verotina

Verotina: An Identity Defined by the SSRI Class

Verotina is a prescription-only synthetic medication classified as an antidepressant and a psychotropic agent. Its active ingredient is Fluoxetine (Fluoxetine Hydrochloride), a compound that belongs specifically to the Selective Serotonin Reuptake Inhibitor (SSRI) pharmacological class. This classification distinguishes it as a first-line therapy for certain conditions. It is commonly used as an initial option for supporting patients in achieving mental stability. The medication is administered orally and is typically available as a capsule, tablet, or oral solution.

Composition and General Therapeutic Purpose

Verotina is a single active ingredient product, meaning its therapeutic effect stems exclusively from the Fluoxetine Hydrochloride it contains, combined with pharmaceutical excipients. As a synthetic compound, its primary purpose is to help regulate and stabilize emotional states by influencing the brain's signaling processes.

Fluoxetine functions by selectively inhibiting the reuptake of the neurotransmitter serotonin, thus increasing its concentration in the synapse. This sustained increase in serotonin activity is the core mechanism that supports the stabilization of mood and contributes to a more balanced and regulated mental state over time. This targeted action is used to support individuals experiencing persistent emotional strain.

Regulatory References

  1. NIH/StatPearls

What side effects are possible with Verotina?

Possible Side Effects and Safety Information

The adverse effects of Verotina (Fluoxetine Hydrochloride) are officially documented according to regulatory standards, classifying reactions by frequency and the body system affected. These descriptions reflect the high-level safety patterns listed in government prescribing information.

Frequency-Classified Adverse Reactions

The most commonly observed reactions involve the nervous and gastrointestinal systems. Reactions categorized as Very Common (ge 1 in 10 patients) include insomnia, headache, diarrhoea, and nausea. Effects listed as Common (ge 1 in 100 to < 1 in 10 patients) include anxiety, decreased sexual drive (libido), dizziness, tremor, dry mouth, and anorexia leading to weight loss. These common effects are often noted as being more prominent at the initiation of treatment.

System-Organ Classes and Serious Reactions

Adverse effects are grouped by system-organ class, including Psychiatric disorders, Nervous system disorders, Gastrointestinal disorders, and Reproductive system disorders.

Regulatory documents specify the potential for serious adverse reactions, though they are rare. These include Serotonin Syndrome (a potentially life-threatening condition involving changes in mental status and neuromuscular function) and Severe Skin Reactions. Official labeling carries a warning regarding an increased risk of Suicidal Ideation and Behavior, particularly in children, adolescents, and young adults (up to age 24), primarily during the initial phase of therapy.

Population-Specific Safety Notes

The medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs). For individuals with Hepatic Impairment, consideration is required as the drug's clearance may be reduced. Pediatric patients require monitoring for growth and pubertal development in addition to behavioral risk. Association with an increased Bone Fracture Risk has been observed in long-term exposure studies.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose with Verotina (Fluoxetine) is officially documented to present with several clinical manifestations. These typically include signs such as drowsiness, tremor, nausea, vomiting, tachycardia (rapid heartbeat), stupor, and syncope (fainting). Pyrexia (fever) and hypotension are also among the documented findings.

Regulatory prescribing information highlights the potential for severe or life-threatening outcomes that require urgent medical attention. These documented risks include seizures, significant QT prolongation, and dangerous cardiac electrical abnormalities such as ventricular arrhythmia and Torsades de Pointes. Furthermore, severe systemic reactions such as Serotonin Syndrome or Neuroleptic Malignant Syndrome-Like events are specifically referenced in the context of overdose.

Emergency Actions and Management

Due to the risk of severe cardiac and neurological complications, immediate medical attention must be sought in all suspected cases of overdose. The official management plan mandates ensuring an adequate airway, oxygenation, and ventilation as primary steps. Because no specific antidote is known for Verotina, treatment consists exclusively of general symptomatic and supportive treatment.

Continuous professional monitoring is required, specifically the mandatory observation of vital signs and a continuous ECG (electrocardiogram) to check for cardiac rhythm changes. Supportive measures, such as the use of activated charcoal, are described to help limit drug absorption. Patients with hepatic impairment may require a prolonged period of monitoring due to altered drug elimination.

Therapeutic Uses of Verotina

What Verotina Treats: Main Uses and Benefits

Verotina is commonly used to help manage symptoms across therapeutic domains that create noticeable functional strain. The medication is generally applied across contexts where additional symptomatic support is needed.

Core Therapeutic Areas

Its application in supporting persistent mood disturbances is a relevant therapeutic area, generally including conditions such as Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, and Bulimia Nervosa. It is also commonly used to help with the cyclical mood shifts and tension associated with Premenstrual Dysphoric Disorder (PMDD). Its application is relevant for supporting stability by easing the overall symptom burden, which may help patients cope more steadily with chronic or recurrent emotional strain.

“It is commonly used to help manage symptoms of persistent low mood and a lack of interest in activities.”


Quick Fact: Supportive Management for Obsessive and Anxious Symptoms

Verotina is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as intrusive thoughts and the sudden, disabling episodes of fear, assisting with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Based on official government regulatory documents for its active substance (Fluoxetine), eligibility to use this medicine is strictly defined by specific exclusions and required precautions.

Populations That Must NOT Use This Medicine (Contraindications)

Contraindicated Group Basis of Exclusion
Known Hypersensitivity History of allergic reaction (e.g., rash, angioedema) to the drug or its components.
Co-administration with MAOIs Concurrent use with Monoamine Oxidase Inhibitors (MAOIs) or use within 14 days of stopping an MAOI.
Co-administration with Pimozide Concurrent use is prohibited due to the risk of drug interaction and QTc prolongation.
Co-administration with Thioridazine Concurrent use is prohibited; Thioridazine must not be used within 5 weeks of stopping this medicine.

Populations Requiring Restricted or Conditional Use

  • Pediatric Patients: Use is not established for children under 7 years of age. Use in children 7 years and older is restricted to specific approved conditions (e.g., OCD, Major Depressive Disorder in some age groups) and requires careful monitoring.
  • Hepatic Impairment: Patients with liver cirrhosis require a lower or less frequent dosage due to decreased drug clearance.
  • Pregnancy: Use is permitted only if the potential benefit justifies the potential risk to the fetus; third-trimester exposure requires consideration due to potential neonatal complications.
  • Breastfeeding: Breastfeeding is not recommended as the substance is excreted in human milk.
  • Cardiovascular Conditions: Caution is required in patients with pre-existing risk factors for QT prolongation or arrhythmias.
  • Seizure History: Use with caution in patients with a history of seizures or other conditions that may lower the seizure threshold.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Verotina (Fluoxetine) is documented in regulatory sources to have clinically significant interaction patterns, primarily categorized as pharmacokinetic and pharmacodynamic.

Contraindicated and Restricted Combinations

Co-administration of Verotina is contraindicated with certain substances due to interaction risks formally defined in official labeling. This includes all Monoamine Oxidase Inhibitors (MAOIs), such as psychiatric MAOIs, Linezolid, and intravenous Methylene Blue, owing to the risk of Serotonin Syndrome.

  • Mandatory Separation: Treatment with a psychiatric MAOI must not be started until at least five weeks after stopping Verotina. Conversely, Verotina must not be started within 14 days of stopping a psychiatric MAOI.

The co-administration of Pimozide and Thioridazine is also contraindicated due to the potential for QTc prolongation and elevated plasma levels of the latter.

Pharmacokinetic and Pharmacodynamic Interactions

Verotina is a potent inhibitor of the CYP2D6 enzyme pathway. This pharmacokinetic interaction can lead to increased plasma concentrations (exposure) of co-administered medicinal products metabolized by this enzyme, including certain Tricyclic Antidepressants (TCAs) and Antipsychotics.

Pharmacodynamic interactions include the enhanced risk of Serotonin Syndrome when combined with other serotonergic agents, such as Triptans, Tramadol, Lithium, or the herbal product St. John’s Wort. Co-administration with drugs that interfere with hemostasis, such as NSAIDs and Warfarin, may potentiate the risk of abnormal bleeding, as noted in official documents. Caution is advised when co-administering with other drugs that prolong the QT interval.

In patients with hepatic impairment, conditions that increase fluoxetine exposure may heighten the risk of specific interactions.

Mechanism of Action

How Verotina Works: Mechanism of Action

Dual Serotonin Transporter and Receptor Modulation

Verotina acts by simultaneously blocking the reuptake of serotonin (5-HT) via the Serotonin Transporter (SERT) and directly engaging multiple serotonin receptors, including 5- HT1 A, 5- HT2 A, and 5- HT2 C. This action increases the concentration of available serotonin in the synaptic cleft and modulates the response of postsynaptic nerve cells, thereby affecting signaling in Central Nervous System (CNS) pathways.


Adjustment of Neural Communication and Pathways

The combined serotonergic effects of Verotina initiate a cascade that influences other neurotransmitter pathways, including dopamine and norepinephrine, affecting the activity of neural circuits. This action modulates the relationship between excitatory and inhibitory signals in brain regions that participate in affective and cognitive processing. The resulting physiological effect is an adjustment of nerve cell communication, which influences neuroplasticity within these neural pathways.

Dosage and Administration Information

Verotina, whose active ingredient is fluoxetine, is a prescription medication and should be taken exactly as directed by your healthcare provider. It is important to adhere strictly to the prescribed dosage and schedule.

General Administration

  • Verotina is typically taken by mouth once a day, generally in the morning.
  • The medication may be taken with or without food. If you are prescribed a capsule, it should be swallowed whole and not crushed, cut, or chewed.
  • If you have a delayed-release or weekly formulation of fluoxetine, follow the specific instructions for that product carefully, as the dosing schedule will differ from the daily capsule/tablet.

Dosing Schedule

The starting dose for Verotina often begins at a lower level and may be gradually increased by your healthcare provider based on your response to treatment. The usual dose for adults treating Major Depressive Disorder (MDD) is typically 20 mg daily. Never change your dose or stop taking this medication without consulting your doctor.

Situation Action
If you miss a dose (daily regimen) Take the missed dose as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at the same time to compensate for a missed one.
Stopping the medication Do not stop taking Verotina suddenly. Abrupt discontinuation, particularly at higher doses, can lead to withdrawal symptoms. Your doctor will provide a plan to gradually reduce the dose before stopping.

It may take several weeks for the full benefit of Verotina to be felt, so continuous use as prescribed is necessary for effective treatment.

Recent Clinical Evidence

Research evidence / Overview of studies for Verotina


Evidence for Managing Persistent Mood Disturbances (MDD)

Research for Major Depressive Disorder (MDD) was conducted using short-term, placebo-controlled randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time, typically lasting between six and twelve weeks. Research examined outcomes related to the intensity of low mood, loss of interest, and other functional aspects of the condition, using standardized clinician-rated measurement scales. Follow-up research also utilized long-term continuation trials designed to track whether symptoms of depression returned during the continuation phase, with studies exploring time to recurrence or relapse of depressive symptoms.

A distinct body of research explored the use of Verotina in these age groups, including children and adolescents (ge 8 years). While Verotina was evaluated in these age groups, findings were mixed across studies; some trials reported that the difference in symptom scores compared to placebo was small. Data for certain groups are still developing, and scientific discussion continues regarding the consistency of the observed outcomes in the youth population.


Evidence for Treating Specific Anxiety and Obsessive Conditions (OCD and Panic Disorder)

The research base for Obsessive-Compulsive Disorder (OCD) utilized trials designed to measure scores on specific symptom rating tools, such as the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). These research scenarios focused on episodes where intrusive thoughts and repetitive behaviors become more noticeable. Research highlights changes measured during the study period, tracking the reduction in core obsessive and compulsive behaviors in both adults and youth populations.

Research for Panic Disorder utilized short-term, multi-site RCTs. These studies primarily tracked two outcomes: the frequency of acute or disruptive episodes (panic attacks) and the overall change in anxiety and severity ratings. Findings describe patterns observed in the studies where some patients reported being panic-attack-free by the end of the trial period. Comparative evidence with other long-term treatment strategies, beyond the initial follow-up, is still emerging.


Evidence Gaps, Inconsistency, and Areas for Future Research

The research record includes facts such as: Follow-up durations were short in many acute trials, meaning that long-term outcomes are not well characterized across all indications. The consistency of outcomes measured differs across studies, especially those involving pediatric populations, where subgroup findings are uncertain due to small sample sizes. Data for certain groups remain insufficient, and research provides context but not individual predictions, describing group patterns, not personal outcomes.

Key Studies & References

  1. Antidepressants, Selective Serotonin Reuptake Inhibitors (SSRI) Therapeutic Class Review (TCR) - Texas Health and Human Services
  2. Short- and Long-Term Antidepressant Clinical Trials for Major Depressive Disorder in Youth: Findings and Concerns - Frontiers (Analysis of MDD efficacy and placebo response in youth)
  3. Fluoxetine - StatPearls - NCBI Bookshelf (Summary of indications, dosing, and special populations)
  4. Fluoxetine (oral route) - Side effects & dosage - Mayo Clinic (Regulatory overview of all indications: MDD, OCD, Panic, Bulimia, PMDD)

Frequently Asked Questions (FAQ)

Common questions about Verotina (FAQ)

Q: Can Verotina cause changes in weight?

Official product information states that anorexia (loss of appetite) leading to weight loss is a common side effect observed in studies. While regulatory texts document the need for caution if weight loss is a concern for the patient, weight gain is generally not a common effect noted in the product information.

Q: What happens if I forget to take Verotina one day?

The action to take depends on the specific formulation prescribed. For a daily dose, regulatory guidance describes a process where if it is almost time for the next scheduled dose, the missed dose is skipped to resume the normal schedule. For the once-weekly formulation, official information describes taking the missed dose as soon as it is remembered, followed by a return to the regular weekly dosing day.

Q: Do you need to stop Verotina gradually or can you stop all at once?

According to official product information, discontinuing the medication suddenly is not recommended. Abrupt cessation may lead to discontinuation symptoms, which can include effects like dizziness, nausea, or anxiety. Regulatory guidance requires that a healthcare provider manage the gradual reduction of the dose over time.

Q: Does Verotina affect blood pressure?

Official safety warnings identify the need for caution for patients who have pre-existing risk factors for heart rhythm changes (arrhythmias or QTc prolongation). Routine changes to general blood pressure are not commonly listed as an adverse reaction in the regulatory documentation for the general population.

Q: Are there any specific laboratory tests required while taking Verotina?

Routine laboratory testing is not typically required during treatment with this medication. However, official information notes that monitoring for low sodium levels (hyponatremia) is documented as a necessary precaution, especially for older patients or those also taking water pills (diuretics).

Q: Can Verotina be divided or crushed?

The guidance on administration depends on the form prescribed. Regulatory guidance describes that the delayed-release capsule is intended to be swallowed whole and not crushed, cut, or chewed. Instructions for the tablet form may vary depending on the specific product formulation prescribed.

Q: Is Verotina safe to use for older adults?

Official studies have not indicated that age-specific problems limit the usefulness of the medication in older adults. However, older patients may have an increased likelihood of experiencing low sodium levels (hyponatremia), so official texts document the need for caution and potential dose adjustment for this population.

Q: Is it normal to feel a little dizzy when first starting Verotina?

Official safety information indicates that dizziness is listed as a common side effect of the medication. Regulatory documents note that these common effects are often more noticeable when treatment is first initiated.

Q: How long does Verotina stay in your system after you stop taking it?

Due to the long time it takes the body to eliminate the medication and its active components (known as the half-life), its effects and potential for drug interactions can persist in the body for up to five weeks or more after the last dose is taken.

Q: Is Verotina considered a controlled substance?

The medication is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This means it is not categorized as having the same physical addictive or abuse properties as certain other prescription medicines.

Q: What should I do if a minor side effect of Verotina doesn't go away?

Patient educational materials contain a recommendation to consult with the prescribing healthcare provider if any persistent or unwanted side effects cause concern or do not improve. Some minor physical symptoms may decline over the first few months of treatment.

Q: Can Verotina impact sleep patterns?

Official regulatory documents list insomnia (difficulty sleeping) as a Very Common side effect. Additionally, other sleep-related changes, such as general sleep disorder and sedation, are classified as Common side effects.

Q: Are there any major warnings associated with Verotina that are often misunderstood?

Major warnings, such as the risk of Suicidal Ideation and Behavior in certain age groups, are prominently highlighted in regulatory texts. Patient education materials emphasize the importance of close observation and communication with a healthcare provider regarding the emergence of new or worsening behavioral symptoms, especially during the beginning of treatment.

Q: What is the purpose of the different strengths (milligrams) of Verotina?

Different strengths are made available to allow the healthcare provider to appropriately tailor the dose for the patient. This allows for achieving the correct therapeutic level for various approved conditions, age groups, and is essential for following a gradual dose adjustment plan (titration).

Q: Are there any known interactions between Verotina and herbal supplements?

Regulatory sources document a risk of interaction, specifically citing the herbal product St. John’s Wort. Combining this supplement with Verotina can enhance the risk of developing Serotonin Syndrome.

Q: Does Verotina have a risk of addiction or dependence?

The medication is not classified as having physical addictive or abuse potential. However, regulatory texts warn that stopping the medicine suddenly can lead to discontinuation symptoms, which are physical and emotional effects resulting from abrupt cessation, not signs of physical addiction.

Q: What does official information say about discontinuing Verotina use?

Official documentation strongly advises that the medication should not be stopped suddenly. To manage the risk of discontinuation symptoms, regulatory guidance states that a healthcare provider must be consulted to create a plan to gradually reduce the dose over time.

Q: Do the side effects of Verotina change after using it for several months?

Regulatory data notes that some common physical side effects, such as nausea or headache, are often more noticeable when treatment is first initiated. These specific effects may lessen or decline over the first few months of therapy as the body adjusts to the medication.

Q: Can taking Verotina cause stomach upset?

Reactions involving the gastrointestinal system are among the most common reported. Regulatory documents list nausea and diarrhoea as Very Common side effects, and vomiting is also listed as a Common reaction.

Q: Does Verotina cause problems with concentration or memory?

Disturbance in attention is listed in regulatory documents as a Common side effect. However, official information also describes the drug as having a low potential to impair overall cognitive or motor performance, and it is not commonly associated with significant memory issues.

Q: Are there any reports of Verotina affecting mood outside of its intended purpose?

Yes, regulatory warnings note the potential for the emergence of symptoms such as agitation, anxiety, irritability, hostility, hypomania, and mania. These effects may occur, particularly during the initial phase of therapy or following a change in dosage.

Q: How common are serious side effects with Verotina?

Official regulatory documents describe serious adverse reactions, such as Serotonin Syndrome and Severe Skin Reactions, as rare. These reactions are typically classified as occurring in less than 1 in 100 people.

Q: Does alcohol consumption change the way Verotina works?

Official information contains an advisory statement to avoid or limit alcohol use while taking the medication. Combining Verotina with alcohol can increase nervous system side effects, such as increasing dizziness, drowsiness, and difficulty concentrating.

Q: Are there any official resources that explain Verotina in simple terms?

Yes, government health bodies and associated patient organizations provide consumer-friendly information and educational guides about the medication. These resources, such as those from the NIH / MedlinePlus and the FDA, explain the drug in plain language.

How should Verotina be stored and disposed of?

How to Store and Dispose of Verotina?

The official storage and disposal requirements for Verotina (Fluoxetine Hydrochloride) are defined by regulatory documents to ensure product stability and household safety.

Official Storage Requirements

Requirement Type Official Guideline
Temperature & Environment Store at room temperature, generally not exceeding 25 C. Protect from light, excess heat, and moisture (e.g., do not store in the bathroom).
Packaging Keep the medication in the original container and ensure the container is tightly closed.
Child Safety It is mandatory to keep Verotina out of the sight and reach of children and to lock safety caps securely.

Official Disposal Rules

For disposal of unused or expired product, the preferred method is returning the medicine to a drug take-back program or utilizing a mail-back envelope. If take-back options are unavailable, follow local pharmaceutical waste regulations. Regulatory guidance strongly advises against disposal by emptying into drains or releasing into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Verotina found in:

A-Z Index: